



Swansea University  
Prifysgol Abertawe



## Cronfa - Swansea University Open Access Repository

---

This is an author produced version of a paper published in:  
*BMC Cardiovascular Disorders*

Cronfa URL for this paper:  
<http://cronfa.swan.ac.uk/Record/cronfa34512>

---

### **Paper:**

Halcox, J., Banegas, J., Roy, C., Dallongeville, J., De Backer, G., Guallar, E., Perk, J., Hajage, D., Henriksson, K. et al. (2017). Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. *BMC Cardiovascular Disorders*, 17(1)  
<http://dx.doi.org/10.1186/s12872-017-0591-5>

---

This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior permission for personal research or study, educational or non-commercial purposes only. The copyright for any work remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium without the formal permission of the copyright holder.

Permission for multiple reproductions should be obtained from the original author.

Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the repository.

<http://www.swansea.ac.uk/iss/researchsupport/cronfa-support/>

RESEARCH ARTICLE

Open Access



# Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study

Julian P. Halcox<sup>1\*</sup>, José R. Banegas<sup>2</sup>, Carine Roy<sup>3</sup>, Jean Dallongeville<sup>4</sup>, Guy De Backer<sup>5</sup>, Eliseo Guallar<sup>6</sup>, Joep Perk<sup>7</sup>, David Hajage<sup>3</sup>, Karin M. Henriksson<sup>8</sup> and Claudio Borghi<sup>9</sup>

## Abstract

**Background:** Atherogenic dyslipidemia is associated with poor cardiovascular outcomes, yet markers of this condition are often ignored in clinical practice. Here, we address a clear evidence gap by assessing the prevalence and treatment of two markers of atherogenic dyslipidemia: elevated triglyceride levels and low levels of high-density lipoprotein cholesterol.

**Methods:** This cross-sectional observational study assessed the prevalence of two atherogenic dyslipidemia markers, high triglyceride levels and low high-density lipoprotein cholesterol levels, in the study population from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA;  $N = 7641$ ; of whom 51.6% were female and 95.6% were White/Caucasian). The EURIKA population included European patients, aged at least 50 years with at least one cardiovascular risk factor but no history of cardiovascular disease.

**Results:** Over 20% of patients from the EURIKA population have either triglyceride or high-density lipoprotein cholesterol levels characteristic of atherogenic dyslipidemia. Furthermore, the proportions of patients with one of these markers were higher in subpopulations with type 2 diabetes mellitus or those already calculated to be at high risk of cardiovascular disease. Approximately 55% of the EURIKA population who have markers of atherogenic dyslipidemia are not receiving lipid-lowering therapy.

**Conclusions:** A considerable proportion of patients with at least one major cardiovascular risk factor in the primary cardiovascular disease prevention setting have markers of atherogenic dyslipidemia. The majority of these patients are not receiving optimal treatment, as specified in international guidelines, and thus their risk of developing cardiovascular disease is possibly underestimated.

**Trial registration:** The present study is registered with ClinicalTrials.gov (ID: NCT00882336).

**Keywords:** Atherogenic dyslipidemia, Cardiovascular disease, Epidemiology, Risk factors/global assessment

\* Correspondence: j.p.j.halcox@swansea.ac.uk

<sup>1</sup>Institute of Life Sciences 2, Swansea University College of Medicine, Singleton Park, Swansea SA2 8PP, UK

Full list of author information is available at the end of the article



## Background

Although considerable progress has been made in understanding and treating associated risk factors, cardiovascular disease (CVD) remains the leading cause of death among adults under the age of 75 years in Europe [1]. Traditionally recognized risk factors for CVD include age, male sex, smoking, lack of exercise, obesity, hypertension, high levels of low-density lipoprotein cholesterol (LDL-C), type 2 diabetes mellitus (T2DM), and familial predisposition [2]. In addition, other factors, including atherogenic dyslipidemia, and elevated lipoprotein(a) or C-reactive protein (CRP) levels, may also be important considerations when estimating patients' overall CVD risk [2–9]. Atherogenic dyslipidemia has been characterized as a combination of elevated LDL-C and triglyceride (TG) levels, decreased high-density lipoprotein cholesterol (HDL-C) levels, and a preponderance of small-dense LDL-C particles [10]. Here, we use data from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA, ClinicalTrials.gov identifier: NCT00882336), a cross-sectional observational study including data on patients from 12 European countries with at least one traditional CVD risk factor but no history of cardiovascular events [11, 12], to assess the prevalence and treatment of two markers of atherogenic dyslipidemia: elevated TG levels and low HDL-C levels. We have previously assessed the prevalence of elevated levels of CRP in the EURIKA population [9]. Among patients without T2DM not receiving a statin, approximately half had CRP levels of at least 2 mg/l. The impact of CRP and markers of atherogenic dyslipidemia on CVD risk is often underestimated in clinical practice, with a lack of evidence for the prevalence and treatment of the latter. TG and CRP levels are not taken into account in global cardiovascular risk calculators, such as the Systematic Coronary Risk Evaluation (SCORE) algorithm [13] and the risk calculator developed alongside the American College of Cardiology/American Heart Association (ACC/AHA) 2013 guidelines [14].

## Methods

### Study design and participants

EURIKA was a cross-sectional study carried out in 12 European countries (Austria, Belgium, France, Germany, Greece, Norway, Russia, Spain, Sweden, Switzerland, Turkey, and the UK) [11]. Included patients were aged 50 years or older and had at least one risk factor for CVD but no history of cardiovascular events. Data collection started in May 2009 and ended in January 2010, with a 3-month data-collection period for each country. The study protocol was approved by the appropriate clinical research ethics committees in each participating country, and all patients provided signed informed consent. The methods for the study have been reported

in detail elsewhere [12]. Briefly, the study sample was selected in a two-stage process that involved the random selection of both physicians and patients [12, 15]. In the first stage, primary care physicians (PCPs) and specialists involved in CVD prevention (including cardiologists, endocrinologists, and internal medicine specialists) were randomly selected for invitation to participate using the OneKey database (Cegedim Dendrite, Boulogne-Billancourt, France) [16]. In total, 809 physicians (approximately 60 per country) agreed to participate in EURIKA, 64% of whom were PCPs [15]. In the second stage, participating physicians sequentially invited patients who met the selection criteria (aged  $\geq 50$  years, who were free from CVD but with at least one major cardiovascular risk factor [dyslipidemia, hypertension, current smoker, T2DM, or obesity]). Hypertension was defined as having a systolic blood pressure (SBP) of at least 140 mmHg, a diastolic blood pressure (DBP) of at least 90 mmHg, or receiving treatment with antihypertensive medications. Approximately 600 patients were included per country, with a final sample size of 7641.

### Assessment of CVD risk factors

Demographic information and other details of participating patients were gathered from medical records and patient interviews. For each patient, a physical examination was conducted, blood pressure measured, and a 12-h fasting blood sample collected within 1 day of the initial outpatient consultation [12]. Blood pressure was measured under standardized conditions, and blood sample analysis was performed at a central laboratory (BioAnalytical Research Corporation, Ghent, Belgium), with the exception of patients in Russia (approximately 5% of the total patient population), for whom a laboratory analysis was performed locally. HDL-C concentration was measured using a modified enzymatic method, total cholesterol concentration using the cholesterol oxidase/p-aminophenazone (CHOD-PAP) method, TG concentration using the glycerol-3-phosphate-oxidase/p-aminophenazone (GPO-PAP) method, and CRP levels using a high-sensitivity immunoturbidimetric method (all using the Roche Modular P chemistry analyzer [Roche Diagnostics, Indianapolis, IN, USA]). LDL-C concentration was calculated by the Friedewald formula [17]. The ACC/AHA risk calculator was used to calculate 10-year CVD risk scores, and the version of the SCORE algorithm updated to consider patients' total cholesterol and HDL-C levels as independent variables (SCORE-HDL) [6, 13, 14, 18]. Patients were considered to be at high CVD risk if they had a score of at least 7.5% when using the ACC/AHA risk calculator, or at least 5% when using the SCORE-HDL algorithm.

High TG levels were defined as those of at least 2.3 mmol/l (200 mg/dl), and low HDL-C levels as those

lower than 1.0 mmol/l (40 mg/dl) in men and lower than 1.3 mmol/l (50 mg/dl) in women. For statin treatment, therapy was categorized as low or moderate intensity (pravastatin 5–40 mg/day, simvastatin 2.5–80 mg/day, lovastatin 10–80 mg/day, fluvastatin 10–80 mg/day, atorvastatin 5–40 mg/day, or rosuvastatin 5–20 mg/day), or high intensity (atorvastatin  $\geq$ 40 mg/day or rosuvastatin  $\geq$ 20 mg/day).

### Statistical analyses

Data are presented as mean and standard deviation for continuous variables, and as frequency and percentage for categorical variables. Comparisons between groups were performed using Student's *t*-tests for normally distributed continuous variables, Mann–Whitney U tests for continuous variables that were not normally distributed, and  $\chi^2$  or Fisher's exact tests for categorical variables, as appropriate. A *p* value below 0.05 was considered significant. Multivariate logistic regression was performed to assess factors associated with high TG and/ or low HDL-C levels. Variables considered in the multivariate analysis included country of origin, age, sex, hypertension, obesity, T2DM status, smoking status, total cholesterol levels, CRP levels, use of  $\beta$ -blockers, use of  $\alpha$ -adrenergic antagonists, and use of diuretics. A stepwise (bidirectional) selection method was used to keep only those variables statistically significantly associated at the *p* < 0.05 level in the final model. Statistical analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).

## Results

### Overall patient characteristics

The EURIKA study population consisted of 7641 patients with a mean age of 63.2 years, of whom 48.4% were men and of whom 95.6% were White/Caucasian (Table 1). Mean body mass index (BMI) was 28.9 kg/m<sup>2</sup>, 21.0% of patients were current smokers, and 26.8% of participants had T2DM. Mean alcohol consumption of the EURIKA study population was 5.7 units/week, and 19.8% of patients reported undertaking no physical exercise. Almost three-quarters (72.8%) of patients had hypertension.

### Prevalence of high TG and/or low HDL-C levels

Among the overall population that included treated and untreated patients, a total of 1591 patients (20.8%) were classified as having high TG levels ( $\geq$  2.3 mmol/l), 1691 (22.1%) had low HDL-C levels (men: < 1.0 mmol/l; women: < 1.3 mmol/l), and 759 (9.9%) had both high TG and low HDL-C levels (Table 1; Fig. 1). A very small proportion of patients in the overall population had very high TG levels (> 5 mmol/L [1.9%]; > 10 mmol/L [0.3%]). Similarly, only 0.1% of the EURIKA population

had very low HDL-C levels (< 0.5 mmol/L). The mean ages of patients in the subpopulations with high TG levels, low HDL-C levels, or both were similar to that of the overall population, as were mean SBP, DBP, and the proportions of patients with hypertension. There were higher proportions of patients classified as obese (BMI  $\geq$  30 kg/m<sup>2</sup>) in the subpopulations with high TG levels, low HDL-C levels, or both than in the overall population. There was a higher proportion of men with high TG levels than women in the patient population; conversely, the proportion of women was higher among patients with low HDL-C levels when compared with men. The proportion of patients who had T2DM was higher among patients with markers of atherogenic dyslipidemia than in the overall population. There were patients within the EURIKA population, both male and female, exceeding the recommended weekly limit of alcohol consumption. There were similar proportions of patients undertaking no physical exercise in the subpopulations with high TG levels, low HDL-C levels, or both to those in the overall population. We observed cross-country variation in the proportions of patients with markers of atherogenic dyslipidemia (Additional file 1: Table S1).

### Treatment of high TG and/or low HDL-C levels

With regard to treatment, over half of patients in the overall population and in the subpopulations with markers of atherogenic dyslipidemia were not receiving any form of lipid-lowering therapy (LLT, Table 1). Of patients receiving LLT, most were receiving a statin alone. Only small proportions of patients were receiving ezetimibe, a fibrate, or nicotinic acid. Of those patients receiving a statin, most were receiving a low- or moderate-intensity statin; only a small proportion of patients ( $\leq$  5%) were receiving a high-intensity statin (Fig. 2).

### Differences in the prevalence of high TG and/or low HDL-C levels according to statin treatment, T2DM, and CVD risk status

Patients in the overall population were described according to whether or not they were receiving statin therapy, and then further stratified according to the presence or absence of T2DM, and then, among patients without T2DM, overall CVD risk assessed using either the ACC/AHA or SCORE-HDL risk calculators [6, 14]. Higher proportions of patients with T2DM were found to have high TG and/or low HDL-C levels than patients without T2DM (Fig. 3). Among patients without T2DM, greater proportions of patients in the higher overall CVD risk categories had high TG and/or low HDL-C levels than patients in lower overall CVD risk categories. These trends were observed in both statin-treated and non-statin-treated patients. Given that the SCORE-HDL and

**Table 1** Patient characteristics and treatment

	Overall (N = 7641)	High TG (n = 1591)	Low HDL-C (n = 1691)	High TG and low HDL-C (n = 759)
Age (year)	63.2 (9.0)	61.5 (8.4)	62.0 (8.8)	60.8 (8.5)
Sex				
Male (n, %)	3696 (48.4)	903 (56.8)	623 (36.8)	330 (43.5)
Female (n, %)	3945 (51.6)	688 (43.2)	1068 (63.2)	429 (56.5)
Race				
White/Caucasian (n, %)	6675 (95.6)	1408 (94.9)	1515 (94.3)	681 (94.7)
Middle East/North African (n, %)	74 (1.1)	15 (1.01)	23 (1.4)	9 (1.3)
South Asian (n, %)	63 (0.9)	16 (1.01)	21 (1.3)	6 (0.8)
Other Asian countries (n, %)	34 (0.5)	10 (0.7)	8 (0.5)	2 (0.3)
South American origin (n, %)	22 (0.3)	6 (0.4)	8 (0.5)	4 (0.6)
Sub-Saharan (n, %)	15 (0.2)	1 (0.1)	2 (0.1)	1 (0.1)
Caribbean (n, %)	14 (0.2)	2 (0.1)	2 (0.1)	1 (0.1)
Other (n, %)	82 (1.2)	26 (1.8)	28 (1.7)	15 (2.1)
Current smoker (n, %)	1608 (21.0)	393 (24.7)	397 (23.5)	201 (26.5)
BMI (kg/m <sup>2</sup> )	28.9 (5.5)	30.6 (5.4)	30.9 (5.8)	31.3 (5.4)
≥ 30 kg/m <sup>2</sup> (n, %)	2788 (37.0)	783 (49.6)	858 (50.7)	410 (54.0)
T2DM <sup>a</sup> (n, %)	2046 (26.8)	562 (35.3)	617 (36.5)	305 (40.2)
Blood pressure				
Hypertension <sup>b</sup> (n, %)	5559 (72.8)	1193 (75.2)	1278 (75.6)	564 (74.3)
SBP (mmHg)	135.1 (16.6)	136.9 (16.7)	135.5 (17.1)	136.0 (17.0)
DBP (mmHg)	80.9 (9.9)	82.3 (10.1)	81.7 (10.0)	82.5 (9.9)
Serum lipid levels				
TC (mmol/l)	5.5 (1.1)	5.9 (1.2)	5.2 (1.2)	5.7 (1.2)
LDL-C (mmol/l)	3.2 (1.0)	3.3 (1.1)	3.1 (1.0)	3.2 (1.0)
Non-HDL-C (mmol/l)	4.0 (1.1)	4.7 (1.2)	4.2 (1.2)	4.7 (1.2)
TG (mmol/l)	1.8 (1.3)	3.4 (1.9)	2.6 (2.0)	3.8 (2.5)
HDL-C (mmol/l)	1.4 (0.4)	1.2 (0.3)	1.0 (0.2)	1.0 (0.2)
CRP (mg/l)	4.2 (8.7)	4.4 (6.3)	6.0 (12.2)	5.0 (7.5)
LLT				
At least one LLT (n, %)	3278 (42.9)	757 (47.6)	749 (44.3)	349 (46.0)
Statin alone (n, %)	2862 (37.5)	598 (37.6)	617 (36.5)	258 (34.0)
Statin + other LLT (n, %)	178 (2.3)	74 (4.7)	57 (3.4)	43 (5.7)
Other LLT alone (n, %)	238 (3.1)	85 (5.3)	75 (4.4)	48 (6.3)
Ezetimibe (n, %)	151 (2.0)	57 (3.6)	45 (2.7)	35 (4.6)
Fibrate (n, %)	220 (2.9)	84 (5.3)	68 (4.0)	45 (5.9)
Nicotinic acid (n, %)	6 (0.1)	3 (0.2)	4 (0.2)	3 (0.4)
Alcohol consumption <sup>c</sup>				
(units/week)	5.7 (11.3)	6.4 (12.2)	3.2 (6.4)	3.6 (6.8)
> 14 units/week (male; n, %)	529 (17.8)	129 (18.0)	47 (9.6)	27 (10.3)
> 7 units/week (female; n, %)	272 (8.9)	49 (9.4)	43 (5.5)	22 (6.9)

**Table 1** Patient characteristics and treatment (Continued)

Physical exercise				
No exercise (n, %)	1489 (19.8)	368 (23.5)	406 (24.3)	191 (25.5)
Only light physical activity per week (n, %)	3782 (50.2)	807 (51.5)	910 (54.6)	403 (53.8)
Heavy physical activity 1–2 times per week (n, %)	1232 (16.4)	220 (14.1)	203 (12.2)	90 (12.0)
Heavy physical activity $\geq 3$ times per week (n, %)	1026 (13.6)	171 (10.9)	149 (8.9)	65 (8.7)

Data are mean (standard deviation) unless otherwise indicated

High TG:  $\geq 2.3$  mmol/l. Low HDL-C:  $< 1.0$  mmol/l in men and  $< 1.3$  mmol/l in women

<sup>a</sup>Considered present if the diagnosis was documented in the medical records

<sup>b</sup>SBP  $\geq 140$  mmHg, DBP  $\geq 90$  mmHg, or receiving antihypertensive medication

<sup>c</sup>Moderate alcohol consumption of 14 units/week (male) and 7 units/week (female) is outlined in the 2016 ESC/EAS guidelines for management of dyslipidemias [3]

Abbreviations: BMI body mass index, CRP C-reactive protein, DBP diastolic blood pressure, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, LLT lipid-lowering therapy, SBP systolic blood pressure, T2DM type 2 diabetes mellitus, TC total cholesterol, TG triglyceride

ACC/AHA risk calculators are valid only for assessing risk in routine clinical practice in patients up to 65 and 79 years of age, respectively, we went further in our analysis and stratified according to these age limits (Additional file 2: Figure S1 and Additional file 3: Figure S2). For the subgroups of patients up to the age of 65 years (SCORE-HDL) and 79 years (ACC/AHA), the proportions of patients with high TG and/or low HDL-C levels were similar to or slightly larger than the corresponding CVD risk groups for the whole population.


#### Factors associated with high TG and/or low HDL-C levels

Factors significantly associated with high TG levels, low HDL-C levels, or both were assessed using multivariate analysis ( $p < 0.0001$ ; Fig. 4). Female sex was positively associated with low HDL-C status but negatively associated with high TG levels. Other cardiovascular risk factors, including T2DM, obesity, smoking, and hypertension (indicated by the use of  $\beta$ -blockers) were positively associated


with markers of atherogenic dyslipidemia. The association of markers of atherogenic dyslipidemia with CRP levels was found to be significant only after adjusting for confounding factors among patients with low HDL-C levels. Some variation in patients' likelihood of having markers of atherogenic dyslipidemia was seen between countries of origin, when assessed relative to the UK.

#### Association between high TG and/or low HDL-C levels and CRP

In the overall population, mean CRP was 4.2 mg/l, and this was increased in patients with high TG levels (4.4 mg/l), low HDL-C levels (6.0 mg/l), and both (5.0 mg/l) (Table 1). Patients in the overall population with high TG levels and/or low HDL-C levels were categorized by plasma CRP concentrations into two subpopulations: CRP lower than 1 mg/l, 1– $< 3$  mg/l, or at least 3 mg/l; and CRP lower than 2 mg/l or at least 2 mg/l. Greater proportions of patients had CRP levels of either



**Fig. 1** Prevalence of high TG and/or low HDL-C levels in the EURIKA population. Percentages indicated are of the total EURIKA population ( $N = 7641$ ). High TG:  $\geq 2.3$  mmol/l. Low HDL-C:  $< 1.0$  mmol/l in men and  $< 1.3$  mmol/l in women Abbreviations: EURIKA European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice, HDL-C high-density lipoprotein cholesterol, TG triglyceride



at least 2 mg/l or at least 3 mg/l among those with high TG levels and/or low HDL-C levels than in the overall population, with between approximately 60 and 70% of patients with markers of atherogenic dyslipidemia having CRP levels of at least 2 mg/l, and between 45 and 50% having CRP levels of at least 3 mg/l (Fig. 5).


## Discussion

We have analyzed the number of patients with high levels of TG and/or low levels of HDL-C, two markers of atherogenic dyslipidemia, in the large clinical EURIKA population. We have shown that 20.8% of patients had high TG levels, 22.1% had low HDL-C levels, and 9.9% had both high TG and low HDL-C levels. Very few patients in our cohort had very high TG levels or very low HDL-C levels; it is likely that other comorbidities or underlying genetic factors may affect these individuals. Our analysis also reveals that the proportion of patients with T2DM (who are already considered to be at high risk of CVD) with high TG and/or low HDL-C levels is higher than that of patients without T2DM. In addition, when categorizing patients without T2DM according to the ACC/AHA or SCORE-HDL risk calculators, larger proportions of patients with high TG and/or low HDL-C levels are in the higher risk categories than in the lower risk categories. Cross-country variation in the proportions of patients with high TG and/or low HDL-C levels was observed and could be a consequence of genetic, cultural or socio-economic factors that have been discussed elsewhere [11]. We are unable to provide definitive explanations in the analysis presented here. Our multivariate analysis revealed that female sex was positively associated with low HDL-C status, which may

reflect the specific selection criteria for the EURIKA population as females have higher HDL-C levels than males in the general population. Thus, our data suggest that European women with at least one cardiovascular risk factor but no history of cardiovascular disease are actually more likely than men to have a low HDL-C status.

The EURIKA study has provided important insights into the effectiveness of current practices related to primary CVD prevention in Europe [9, 11, 19]. The primary analysis of the EURIKA data demonstrated that a substantial proportion of patients had CVD risk factors that remained uncontrolled, despite receiving treatment [11]. A follow-up analysis of CRP levels in the EURIKA population revealed that among patients without T2DM who were not receiving statin treatment, more than one-third had CRP levels of at least 3 mg/l, while almost half had CRP levels of at least 2 mg/l [9]. Here, our analysis of CRP levels demonstrates that a greater proportion of patients with high TG and/or low HDL-C levels also have low-grade inflammation, evident by elevated CRP levels, than in the overall at-risk population. These patients are likely to be at an even higher risk of CVD than those with either atherogenic dyslipidemia or elevated CRP levels alone.

We have previously reported on the proportions of patients in EURIKA who were not receiving any form of LLT and who had uncontrolled LDL-C levels [19]. Elevated LDL-C levels are among the primary causal risk factors for cardiovascular disease, and are a component of the atherogenic dyslipidemia profile [2]. Over one-third of patients defined as being at high risk of CVD in our previous analysis were not receiving any form of




**Fig. 3** Proportion of patients with markers of atherogenic dyslipidemia, according to T2DM status and CVD risk. **(a)** Non-statin - treated patients; **(b)** statin-treated patients. Data within bars are *n* (%). High TG:  $\geq 2.3$  mmol/l. Low HDL-C:  $< 1.0$  mmol/l in men and  $< 1.3$  mmol/l in women. <sup>a</sup>ACC/AHA risk calculator [14]. <sup>b</sup>SCORE-HDL risk calculator [6, 18]. *Abbreviations:* ACC American College of Cardiology, AHA American Heart Association, CVD cardiovascular disease, HDL-C high-density lipoprotein cholesterol, SCORE-HDL Systematic Coronary Risk Evaluation-high-density lipoprotein, T2DM type 2 diabetes mellitus, TG triglyceride

LLT [19]. Moreover, LDL-C levels were controlled in only 40% of these patients at high risk of CVD who were receiving LLT [19]. Findings from the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolemia (CEPHEUS) were similar; only 49.4% of patients achieved their recommended LDL-C levels [20]. A literature review from 2004 also reported a widespread failure in the attainment of recommended lipid levels in patients treated with LLT [21]. Similarly, in the current analysis, we observed that approximately 55% of patients with high TG levels, low HDL-C levels, or both were not taking any form of LLT. Furthermore, of those patients treated with statins, the majority were using low-

intensity statins. These observations build on our previous arguments that there is a clear opportunity to improve rates of treatment for primary CVD prevention, and for patients with dyslipidemia in particular.


Whether or not TG levels are a causal risk factor for CVD is debated [22, 23]; patients with high TG levels often have additional CVD risk factors; TG levels in human plasma are highly variable and are strongly associated with low HDL-C levels, which makes it difficult to separate the contributions of these two components [22–25]. Nevertheless, several population studies and meta-analyses have shown a significant link between TG levels and CVD risk, independent of other CVD risk



factors, including HDL-C levels [26–28]. A topic of debate has been whether measuring non-fasting TG levels is a better predictor of CVD than measuring fasting TG levels, with some studies showing a stronger association between non-fasting TG levels and CVD risk than fasting TG levels [24, 29]. European guidelines have previously recommended the measurement of fasting TG levels, as was done in EURIKA, owing to a lack of standardization of non-fasting TG measurements [30]. Guidelines recommend lifestyle interventions in patients with moderately elevated TG levels (e.g. reduction in alcohol consumption, dietary modifications, or increased aerobic exercise) [23]. A reduction in alcohol

consumption is of particular importance, as patients with elevated TG levels are likely to experience further increases from consuming even small quantities of alcohol [3]. Our analysis reveals that within the EURIKA population, small proportions of patients with elevated TG levels are consuming more units of alcohol than the recommended weekly limit. Furthermore, almost 20% of the overall population reported undertaking no physical exercise. In patients with TG levels above 500 mg/dl, pharmacological intervention in the form of fibrates, niacins, or omega-3 fish oils should be considered [23].

The EURIKA study has the strength of allowing analysis of data from a large sample of patients from



**Fig. 5** Association between markers of atherogenic dyslipidemia and CRP. **(a)** CRP levels of < 1 mg/L, 1–< 3 mg/L or ≥ 3 mg/L; **(b)** CRP levels < 2 mg/L or ≥ 2 mg/L. Data were missing for 76 patients in the overall population, and for 1 patient in each of the dyslipidemia groups. Data within bars are *n* (%). High TG: ≥ 2.3 mmol/l. Low HDL-C: < 1.0 mmol/l in men and < 1.3 mmol/l in women. *Abbreviations:* CRP C-reactive protein, HDL-C high-density lipoprotein cholesterol, TG triglyceride

multiple European countries according to standardized procedures. Almost all blood samples were analyzed at the same location, with the exception of patients from Russia. A limitation of the study, however, is that it is cross-sectional, and therefore does not allow conclusions to be drawn regarding the longitudinal association of individual factors with CVD risk. The EURIKA study recruited individuals over 50 years of age with at least one major CVD risk factor, including dyslipidemia. Therefore, the proportion of patients identified with low HDL-C and high TG levels is likely to be greater than in

people of the same age in the general population. Previous cohort studies investigating the predictive power of HDL-C levels in CVD risk have measured HDL-C using precipitation methods. In EURIKA, HDL-C levels were measured using an enzymatic method; it has been demonstrated that enzymatic methods result in higher recorded HDL-C levels than precipitation methods [31]. Therefore, it is possible that we have underestimated the proportion of the cohort with low HDL-C levels. The participation rate among invited physicians was also low; however, potential patient selection bias is likely to have

been reduced by the high participation rate among invited patients, and the randomized method of patient selection. Finally, we did not calculate the ratio of TG to HDL-C concentrations in the EURIKA study; however, this marker has been proposed to correlate with insulin resistance and thus could be used to identify patients at risk of CVD [32].

## Conclusions

A considerable proportion of primary prevention patients at risk of CVD in routine clinical practice have high levels of TG and low levels of HDL-C. Many of these patients also have evidence of elevated CRP levels, reflecting low-grade inflammation. Therefore, these patients' absolute CVD risk may be underestimated by current European and US global risk calculators. These patients may benefit from more intensive or better-tailored treatment options to address their overall CVD risk, in accordance with evidence-based guidelines.

## Additional files

**Additional file 1: Table S1.** Prevalence of high TG and/or low HDL-C levels in the EURIKA population by country. Data are (n, %). High TG:  $\geq 2.3$  mmol/l. Low HDL-C:  $< 1.0$  mmol/l in men and  $< 1.3$  mmol/l in women. *Abbreviations:* HDL-C high-density lipoprotein cholesterol, TG triglyceride (DOCX 15 kb)

**Additional file 2: Figure S1.** Proportion of non-statin-treated patients with markers of atherogenic dyslipidemia, according to T2DM status, CVD risk, and age: (a) according to SCORE-HDL categories; (b) according to ACC/AHA categories. Data within bars are n (%). High TG:  $\geq 2.3$  mmol/l. Low HDL-C:  $< 1.0$  mmol/l in men and  $< 1.3$  mmol/l in women. *Abbreviations:* ACC American College of Cardiology, AHA American Heart Association, CVD cardiovascular disease, HDL-C high-density lipoprotein cholesterol, SCORE-HDL Systematic Coronary Risk Evaluation-high-density lipoprotein, T2DM type 2 diabetes mellitus, TG triglycerides (PDF 1099 kb)

**Additional file 3: Figure S2.** Proportion of statin-treated patients with markers of atherogenic dyslipidemia, according to T2DM status, CVD risk and age: (a) according to SCORE-HDL categories; (b) according to ACC/AHA categories. Data within bars are n (%). High TG:  $\geq 2.3$  mmol/l. Low HDL-C:  $< 1.0$  mmol/l in men and  $< 1.3$  mmol/l in women. *Abbreviations:* ACC American College of Cardiology, AHA American Heart Association, CVD cardiovascular disease, HDL-C high-density lipoprotein cholesterol, SCORE-HDL Systematic Coronary Risk Evaluation-high-density lipoprotein, T2DM type 2 diabetes mellitus, TG triglycerides (PDF 1090 kb)

## Abbreviations

ACC: American College of Cardiology; AHA: American Heart Association; BMI: Body mass index; CEPHEUS: Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolemia; CI: Confidence interval; CRP: C-reactive protein; CVD: Cardiovascular disease; DBP: Diastolic blood pressure; EURIKA: European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; LLT: Lipid-lowering therapy; OR: Odds ratio; PCP: Primary care physician; SBP: Systolic blood pressure; SCORE: Systematic Coronary Risk Evaluation; SCORE-HDL: Systematic Coronary Risk Evaluation-high-density lipoprotein; T2DM: Type 2 diabetes mellitus; TC: Total cholesterol; TG: Triglyceride

## Acknowledgments

Writing support was provided by Gary Male, PhD from Oxford PharmaGenesis, Oxford, UK and was funded by AstraZeneca.

## Funding

The EURIKA study was funded by AstraZeneca. The study was run by an independent academic steering committee, which worked under rules agreed a priori that allowed intellectual input of the funder (i.e. the funder contributed ideas to the study design, data analysis, and preparation of the manuscript) while granting the executive and decision making role to the committee. The authors had full access to all data and had final responsibility for the contents of the manuscript and the decision to submit it for publication.

## Availability of data and materials

The EURIKA study database is the property of AstraZeneca. Data requests can be sent for consideration through the portal at [www.astrazenecadclinicaltrials.com](http://www.astrazenecadclinicaltrials.com), which also includes information on the company Clinical Transparency Policy.

## Authors' contributions

Conceived and designed the experiments: JPH, JB, CR, JD, GDB, EG, JP, DH, KMH, CB. Performed the experiments: JPH, JB, CR, JD, GDB, EG, JP, DH, KMH, CB. Analyzed the data: JPH, CR, DH. Wrote the paper: JPH, JB, CR, JD, GDB, EG, JP, DH, KMH, CB. All authors read and approved the final manuscript.

## Competing interests

Julian P. Halcox has received speaker and consulting fees from Abbot Products and AstraZeneca; Claudio Borghi has received speaker and consulting fees from Amgen, Menarini, Novartis, Roche, Sanofi, Servier, and Takeda; Carine Roy has received research funding from AstraZeneca; Jean Dallongeville has received fees from AstraZeneca, Bayer, and Merck Sharp & Dohme. Karin M. Henriksson was an employee of AstraZeneca when this manuscript was initiated but has since retired from this position. The other authors declare that they have no competing interests.

## Consent for publication

Not applicable.

## Ethics approval and consent to participate

The study protocol was approved by the appropriate clinical research ethics committees in each participating country, and all patients provided signed informed consent. The study protocol has been approved by the appropriate clinical research ethics committees in each participating country, and complies with the local regulations for clinical research. Specifically, the protocol was approved by the following ethics committees: Ethics Committee of Hospital Barmherzige Brüder, Vienna, Austria; Ethics Committee University Hospital, Ghent, Belgium; National Commission on Informatics and Liberties, Paris, France; Ethics Committee of the Friedrich-Alexander-University Erlangen-Nuremberg, Germany; Scientific Council of University General Hospital of Ioannina, and the National Organization for Medicines (EOF), Greece; Regional Committee for Ethics in Medicine and Research Sor-øst B (REK Sor-øst B), Oslo, Norway; Independent Interdisciplinary Ethics Committee, Moscow, Russia; Clinical Research Ethics Committee of La Paz University Hospital, Madrid, Spain; Ethics Committee of the University Hospital of Linköping, Sweden; Ethics Committee for Ambulatory Clinical Research, Medical Association of Geneva, Switzerland; Research Ethics Committee of Medical Faculty, Gazi University, Ankara, Turkey; Brent Primary Care Trust Applied Research Unit, National Health Service, London, UK.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Author details

<sup>1</sup>Institute of Life Sciences 2, Swansea University College of Medicine, Singleton Park, Swansea SA2 8PP, UK. <sup>2</sup>Department of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid/IdiPaz and CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. <sup>3</sup>INSERM CIC-EC 1425 and Département d'Épidémiologie et Recherche Clinique, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France. <sup>4</sup>INSERM U 744, Institut Pasteur de Lille, Université Lille-Nord de France, Lille, France. <sup>5</sup>Department of Public Health, University of Ghent, Ghent, Belgium. <sup>6</sup>Departments of Epidemiology and Medicine and Welch Center of Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. <sup>7</sup>School of Health and Caring

Sciences, Linnaeus University, Kalmar, Sweden. <sup>8</sup>Department of Medical Sciences, Uppsala University, Uppsala, Sweden. <sup>9</sup>Department of Internal Medicine, Ageing and Clinical Nephrology, University of Bologna, Bologna, Italy.

Received: 18 January 2017 Accepted: 5 June 2017

Published online: 17 June 2017

## References

- European cardiovascular disease statistics <http://www.ehnheart.org/cvd-statistics.html> Accessed 18 Oct 2016.
- Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint Task Force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J*. 2016;37(29):2315–81.
- Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. ESC/EAS guidelines for the Management of Dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Atherosclerosis*. 2016;253:281–344.
- Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. *Lancet*. 2014;384(9943):626–35.
- Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. *Eur Heart J*. 2011;32(11):1345–61.
- Cooney MT, Dudina A, De Bacquer D, Fitzgerald A, Conroy R, Sans S, et al. How much does HDL cholesterol add to risk estimation? A report from the SCORE investigators. *Eur J Cardiovasc Prev Rehabil*. 2009;16(3):304–14.
- Cooney MT, Dudina A, De Bacquer D, Wilhelmsen L, Sans S, Menotti A, et al. HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. *Atherosclerosis*. 2009;206(2):611–6.
- Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *N Engl J Med*. 2004;350(14):1387–97.
- Halcox JP, Roy C, Tubach F, Banegas JR, Dallongeville J, De Backer G, et al. C-reactive protein levels in patients at cardiovascular risk: EURIKA study. *BMC Cardiovasc Disord*. 2014;14:25.
- Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. *Circulation*. 1997;95(1):1–4.
- Banegas JR, Lopez-Garcia E, Dallongeville J, Guallar E, Halcox JP, Borghi C, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. *Eur Heart J*. 2011;32(17):2143–52.
- Rodriguez-Artalejo F, Guallar E, Borghi C, Dallongeville J, De Backer G, Halcox JP, et al. Rationale and methods of the European study on cardiovascular risk prevention and Management in Daily Practice (EURIKA). *BMC Public Health*. 2010;10:382.
- Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *Eur Heart J*. 2003;24(11):987–1003.
- Goff DC, Jr., Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Sr., Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. *Circulation*. 2014;129(25 Suppl. 2):S49–73.
- Dallongeville J, Banegas JR, Tubach F, Guallar E, Borghi C, De Backer G, et al. Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study. *Eur J Cardiovasc Prev Rehabil*. 2011;19(3):541–50.
- OneKey [<http://www.i-marches.com/index.php?id=onekey>].
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem*. 1972;18(6):499–502.
- HeartScore – a unique and interactive risk prediction and management system <http://www.escardio.org/Education/Practice-Tools/CVD-prevention-toolbox/HeartScore>. Accessed 18 Oct 2016.
- Halcox JP, Tubach F, Lopez-Garcia E, De Backer G, Borghi C, Dallongeville J, et al. Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe. *PLoS One*. 2015;10(2):e0115270.
- Chiang CE, Ferrieres J, Gotcheva NN, Raal FJ, Shehab A, Sung J, et al. Suboptimal control of lipid levels: results from 29 countries participating in the Centralized pan-Regional Surveys on the Undertreatment of Hypercholesterolemia (CEPHEUS). *J Atheroscler Thromb*. 2016;23(5):567–87.
- Schwandt P, Brady AJ. Achieving lipid goals in Europe: how large is the treatment gap? *Expert Rev Cardiovasc Ther*. 2004;2(3):431–49.
- Harchaoui KE, Visser ME, Kastelein JJ, Stroes ES, Dallinga-Thie GM. Triglycerides and cardiovascular risk. *Curr Cardiol Rev*. 2009;5(3):216–22.
- Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2011;123(20):2292–333.
- Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. *Circulation*. 2008;118(10):993–1001.
- Ginsberg HN, Bonds DE, Lovato LC, Crouse JR, Elam MB, Linz PE, et al. Evolution of the lipid trial protocol of the action to control cardiovascular risk in diabetes (ACCORD) trial. *Am J Cardiol*. 2007;99(12A):561–671.
- Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. *Eur Heart J*. 1998;19(Suppl. Mat):M8–14.
- Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen male study. *Circulation*. 1998;97(11):1029–36.
- Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. *Circulation*. 2007;115(4):450–8.
- Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. *JAMA*. 2007;298(3):299–308.
- Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint Task Force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). *Eur Heart J*. 2012;33:1635–701.
- Langlois MR, Delanghe JR, De Buyzere M, Rietzschel E, De Bacquer D. Unanswered questions in including HDL-cholesterol in the cardiovascular risk estimation. Is time still on our side? *Atherosclerosis*. 2013;226(1):296–8.
- McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. *Ann Intern Med*. 2003;139(10):802–9.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

